Particle accelerator technology company Ion Beam Applications S.A. (IBA) (Euronext Brussels:IBAB) on Thursday announced a new agreement with Shreeji Imaging and Diagnostic Centre Pvt Ltd, an Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals.
The multi-site agreement covers the delivery and installation of four Cyclone KIUBE 300 cyclotrons in Ahmedabad, Nagpur, Kochi, and Bhubaneswar to support the industrial-scale production of fluorine-18 (F-18) labelled compounds and other PET radiopharmaceuticals. The contract is valued at EUR5-7m.
Shreeji's expansion addresses growing demand for PET imaging in India, improving access outside major cities, reducing logistics risks, and creating capacity for new tracers.
The Cyclone KIUBE 300 was chosen for its high beam current, industrial reliability, and upgrade flexibility to support evolving tracer portfolios. IBA's systems will enable GMP-compliant, cost-efficient F-18 production across multiple sites while strengthening its installed base and service network in India. The agreement reinforces IBA's position in nuclear medicine and supports scalable, sustainable growth in PET diagnostics for cancer care.
Ella immunoassay platform gains CE‑IVD approval in the EU
HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer
Celyad Oncology sells C-Cathez catheter to CellProthera
Citius Oncology signs LYMPHIR distribution agreement with Uniphar
Ribo and Madrigal sign global siRNA licensing deal
BillionToOne launches two new add-on liquid biopsy applications for Northstar Select
Iterion Therapeutics reports first patient dosed in clinical study of tegavivint
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
Median Technologies secures FDA clearance for AI lung cancer screening software
Insilico Medicine names new vice president, Clinical Development – Oncology
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001